1
|
Calzuola ST, Newman G, Feaugas T, Perrault CM, Blondé JB, Roy E, Porrini C, Stojanovic GM, Vidic J. Membrane-based microfluidic systems for medical and biological applications. LAB ON A CHIP 2024; 24:3579-3603. [PMID: 38954466 DOI: 10.1039/d4lc00251b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/04/2024]
Abstract
Microfluidic devices with integrated membranes that enable control of mass transport in constrained environments have shown considerable growth over the last decade. Membranes are a key component in several industrial processes such as chemical, pharmaceutical, biotechnological, food, and metallurgy separation processes as well as waste management applications, allowing for modular and compact systems. Moreover, the miniaturization of a process through microfluidic devices leads to process intensification together with reagents, waste and cost reduction, and energy and space savings. The combination of membrane technology and microfluidic devices allows therefore magnification of their respective advantages, providing more valuable solutions not only for industrial processes but also for reproducing biological processes. This review focuses on membrane-based microfluidic devices for biomedical science with an emphasis on microfluidic artificial organs and organs-on-chip. We provide the basic concepts of membrane technology and the laws governing mass transport. The role of the membrane in biomedical microfluidic devices, along with the required properties, available materials, and current challenges are summarized. We believe that the present review may be a starting point and a resource for researchers who aim to replicate a biological phenomenon on-chip by applying membrane technology, for moving forward the biomedical applications.
Collapse
Affiliation(s)
- Silvia Tea Calzuola
- UMR7646 Laboratoire d'hydrodynamique (LadHyX), Ecole Polytechnique, Palaiseau, France.
- Eden Tech, Paris, France
| | - Gwenyth Newman
- Eden Tech, Paris, France
- Department of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milan, Italy
| | - Thomas Feaugas
- Eden Tech, Paris, France
- Department of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milan, Italy
| | | | | | | | | | - Goran M Stojanovic
- Faculty of Technical Sciences, University of Novi Sad, T. D. Obradovića 6, 21000 Novi Sad, Serbia
| | - Jasmina Vidic
- Micalis Institute, INRAE, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| |
Collapse
|
2
|
Saraei N, Dabaghi M, Fusch G, Rochow N, Fusch C, Selvaganapathy PR. Scaled-up Microfluidic Lung Assist Device for Artificial Placenta Application with High Gas Exchange Capacity. ACS Biomater Sci Eng 2024; 10:4612-4625. [PMID: 38904210 DOI: 10.1021/acsbiomaterials.3c01635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/22/2024]
Abstract
Premature neonates with underdeveloped lungs experience respiratory issues and need respiratory support, such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The "artificial placenta" (AP) is a noninvasive approach that supports their lungs and reduces respiratory distress, using a pumpless oxygenator connected to the systemic circulation, and can address some of the morbidity issues associated with ECMO. Over the past decade, microfluidic blood oxygenators have garnered significant interest for their ability to mimic physiological conditions and incorporate innovative biomimetic designs. Achieving sufficient gas transfer at a low enough pressure drop for a pumpless operation without requiring a large volume of blood to prime such an oxygenator has been the main challenge with microfluidic lung assist devices (LAD). In this study, we improved the gas exchange capacity of our microfluidic-based artificial placenta-type LAD while reducing its priming volume by using a modified fabrication process that can accommodate large-area thin film microfluidic blood oxygenator (MBO) fabrication with a very high gas exchange surface. Additionally, we demonstrate the effectiveness of a LAD assembled by using these scaled-up MBOs. The LAD based on our artificial placenta concept effectively increases oxygen saturation levels by 30% at a flow rate of 40 mL/min and a pressure drop of 23 mmHg in room air, which is sufficient to support partial oxygenation for 1 kg preterm neonates in respiratory distress. When the gas ambient environment was changed to pure oxygen at atmospheric pressure, the LAD would be able to support premature neonates weighing up to 2 kg. Furthermore, our experiments reveal that the LAD can handle high blood flow rates of up to 150 mL/min and increase oxygen saturation levels by ∼20%, which is equal to an oxygen transfer of 7.48 mL/min in an enriched oxygen environment and among the highest for microfluidic AP type devices. Such performance makes this LAD suitable for providing essential support to 1-2 kg neonates in respiratory distress.
Collapse
Affiliation(s)
| | | | | | - Niels Rochow
- Nuremberg Department of Pediatrics, Paracelsus Medical University, University Hospital, Nuremberg 90419, Germany
| | - Christoph Fusch
- Nuremberg Department of Pediatrics, Paracelsus Medical University, University Hospital, Nuremberg 90419, Germany
| | | |
Collapse
|
3
|
Roberts TR, Persello A, Harea GT, Vedula EM, Isenberg BC, Zang Y, Santos J, Borenstein JT, Batchinsky AI. First 24-Hour-Long Intensive Care Unit Testing of a Clinical-Scale Microfluidic Oxygenator in Swine: A Safety and Feasibility Study. ASAIO J 2024; 70:535-544. [PMID: 38165978 DOI: 10.1097/mat.0000000000002127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2024] Open
Abstract
Microfluidic membrane oxygenators are designed to mimic branching vasculature of the native lung during extracorporeal lung support. To date, scaling of such devices to achieve clinically relevant blood flow and lung support has been a limitation. We evaluated a novel multilayer microfluidic blood oxygenator (BLOx) capable of supporting 750-800 ml/min blood flow versus a standard hollow fiber membrane oxygenator (HFMO) in vivo during veno-venous extracorporeal life support for 24 hours in anesthetized, mechanically ventilated uninjured swine (n = 3/group). The objective was to assess feasibility, safety, and biocompatibility. Circuits remained patent and operated with stable pressures throughout 24 hours. No group differences in vital signs or evidence of end-organ damage occurred. No change in plasma free hemoglobin and von Willebrand factor multimer size distribution were observed. Platelet count decreased in BLOx at 6 hours (37% dec, P = 0.03), but not in HFMO; however, thrombin generation potential was elevated in HFMO (596 ± 81 nM·min) versus BLOx (323 ± 39 nM·min) at 24 hours ( P = 0.04). Other coagulation and inflammatory mediator results were unremarkable. BLOx required higher mechanical ventilator settings and showed lower gas transfer efficiency versus HFMO, but the stable device performance indicates that this technology is ready for further performance scaling and testing in lung injury models and during longer use conditions.
Collapse
Affiliation(s)
- Teryn R Roberts
- From the Autonomous Reanimation and Evacuation Research Program, The Geneva Foundation, San Antonio, Texas
| | - Antoine Persello
- From the Autonomous Reanimation and Evacuation Research Program, The Geneva Foundation, San Antonio, Texas
| | - George T Harea
- From the Autonomous Reanimation and Evacuation Research Program, The Geneva Foundation, San Antonio, Texas
| | - Else M Vedula
- Bioengineering Division, Draper, Cambridge, Massachusetts
| | | | - Yanyi Zang
- From the Autonomous Reanimation and Evacuation Research Program, The Geneva Foundation, San Antonio, Texas
| | - Jose Santos
- Bioengineering Division, Draper, Cambridge, Massachusetts
| | | | - Andriy I Batchinsky
- From the Autonomous Reanimation and Evacuation Research Program, The Geneva Foundation, San Antonio, Texas
| |
Collapse
|
4
|
Fleck E, Keck C, Ryszka K, Zhang A, Atie M, Maddox S, Potkay J. Toward 3D printed microfluidic artificial lungs for respiratory support. LAB ON A CHIP 2024; 24:955-965. [PMID: 38275173 PMCID: PMC10863644 DOI: 10.1039/d3lc00814b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 01/10/2024] [Indexed: 01/27/2024]
Abstract
Microfluidic artificial lungs (μALs) are a new class of membrane oxygenators. Compared to traditional hollow-fiber oxygenators, μALs closely mimic the alveolar microenvironment due to their size-scale and promise improved gas exchange efficiency, hemocompatibility, biomimetic blood flow networks, and physiologically relevant blood vessel pressures and shear stresses. Clinical translation of μALs has been stalled by restrictive microfabrication techniques that limit potential artificial lung geometries, overall device size, and throughput. To address these limitations, a high-resolution Asiga MAX X27 UV digital light processing (DLP) 3D printer and custom photopolymerizable polydimethylsiloxane (PDMS) resin were used to rapidly manufacture small-scale μALs via vat photopolymerization (VPP). Devices were designed in SOLIDWORKS with 500 blood channels and 252 gas channels, where gas and blood flow channels were oriented orthogonally and separated by membranes on the top and bottom, permitting two-sided gas exchange. Successful devices were post-processed to remove uncured resin from microchannels and assembled with external tubing in preparation for gas exchange performance testing with ovine whole blood. 3D printed channel dimensions were 172 μm-tall × 320 μm-wide, with 62 μm-thick membranes and 124 μm-wide support columns. Measured outlet blood oxygen saturation (SO2) agreed with theoretical models and rated flow of the device was 1 mL min-1. Blood side pressure drop was 1.58 mmHg at rated flow. This work presents the highest density of 3D printed microchannels in a single device, one of the highest CO2 transfer efficiencies of any artificial lung to date, and a promising approach to translate μALs one step closer to the clinic.
Collapse
Affiliation(s)
- Elyse Fleck
- ECLS Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA
| | - Charlise Keck
- ECLS Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA
| | - Karolina Ryszka
- ECLS Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA
| | - Andrew Zhang
- ECLS Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA
| | - Michael Atie
- ECLS Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA
| | - Sydney Maddox
- ECLS Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA
| | - Joseph Potkay
- ECLS Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA
| |
Collapse
|
5
|
Newman G, Leclerc A, Arditi W, Calzuola ST, Feaugas T, Roy E, Perrault CM, Porrini C, Bechelany M. Challenge of material haemocompatibility for microfluidic blood-contacting applications. Front Bioeng Biotechnol 2023; 11:1249753. [PMID: 37662438 PMCID: PMC10469978 DOI: 10.3389/fbioe.2023.1249753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 08/07/2023] [Indexed: 09/05/2023] Open
Abstract
Biological applications of microfluidics technology is beginning to expand beyond the original focus of diagnostics, analytics and organ-on-chip devices. There is a growing interest in the development of microfluidic devices for therapeutic treatments, such as extra-corporeal haemodialysis and oxygenation. However, the great potential in this area comes with great challenges. Haemocompatibility of materials has long been a concern for blood-contacting medical devices, and microfluidic devices are no exception. The small channel size, high surface area to volume ratio and dynamic conditions integral to microchannels contribute to the blood-material interactions. This review will begin by describing features of microfluidic technology with a focus on blood-contacting applications. Material haemocompatibility will be discussed in the context of interactions with blood components, from the initial absorption of plasma proteins to the activation of cells and factors, and the contribution of these interactions to the coagulation cascade and thrombogenesis. Reference will be made to the testing requirements for medical devices in contact with blood, set out by International Standards in ISO 10993-4. Finally, we will review the techniques for improving microfluidic channel haemocompatibility through material surface modifications-including bioactive and biopassive coatings-and future directions.
Collapse
Affiliation(s)
- Gwenyth Newman
- Department of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milan, Italy
- Eden Tech, Paris, France
| | - Audrey Leclerc
- Institut Européen des Membranes, IEM, UMR 5635, Univ Montpellier, ENSCM, Centre National de la Recherche Scientifique (CNRS), Place Eugène Bataillon, Montpellier, France
- École Nationale Supérieure des Ingénieurs en Arts Chimiques et Technologiques, Université de Toulouse, Toulouse, France
| | - William Arditi
- Eden Tech, Paris, France
- Centrale Supélec, Gif-sur-Yvette, France
| | - Silvia Tea Calzuola
- Eden Tech, Paris, France
- UMR7648—LadHyx, Ecole Polytechnique, Palaiseau, France
| | - Thomas Feaugas
- Department of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milan, Italy
- Eden Tech, Paris, France
| | | | | | | | - Mikhael Bechelany
- Institut Européen des Membranes, IEM, UMR 5635, Univ Montpellier, ENSCM, Centre National de la Recherche Scientifique (CNRS), Place Eugène Bataillon, Montpellier, France
- Gulf University for Science and Technology (GUST), Mubarak Al-Abdullah, Kuwait
| |
Collapse
|
6
|
Isenberg BC, Vedula EM, Santos J, Lewis DJ, Roberts TR, Harea G, Sutherland D, Landis B, Blumenstiel S, Urban J, Lang D, Teece B, Lai W, Keating R, Chiang D, Batchinsky AI, Borenstein JT. A Clinical-Scale Microfluidic Respiratory Assist Device with 3D Branching Vascular Networks. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2023; 10:e2207455. [PMID: 37092588 PMCID: PMC10288269 DOI: 10.1002/advs.202207455] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 03/10/2023] [Indexed: 05/03/2023]
Abstract
Recent global events such as COVID-19 pandemic amid rising rates of chronic lung diseases highlight the need for safer, simpler, and more available treatments for respiratory failure, with increasing interest in extracorporeal membrane oxygenation (ECMO). A key factor limiting use of this technology is the complexity of the blood circuit, resulting in clotting and bleeding and necessitating treatment in specialized care centers. Microfluidic oxygenators represent a promising potential solution, but have not reached the scale or performance required for comparison with conventional hollow fiber membrane oxygenators (HFMOs). Here the development and demonstration of the first microfluidic respiratory assist device at a clinical scale is reported, demonstrating efficient oxygen transfer at blood flow rates of 750 mL min⁻1 , the highest ever reported for a microfluidic device. The central innovation of this technology is a fully 3D branching network of blood channels mimicking key features of the physiological microcirculation by avoiding anomalous blood flows that lead to thrombus formation and blood damage in conventional oxygenators. Low, stable blood pressure drop, low hemolysis, and consistent oxygen transfer, in 24-hour pilot large animal experiments are demonstrated - a key step toward translation of this technology to the clinic for treatment of a range of lung diseases.
Collapse
Affiliation(s)
| | | | - Jose Santos
- Bioengineering DivisionDraperCambridgeMA02139USA
| | | | - Teryn R. Roberts
- Autonomous Reanimation and Evacuation (AREVA) Research ProgramThe Geneva FoundationSan AntonioTX78234USA
| | - George Harea
- Autonomous Reanimation and Evacuation (AREVA) Research ProgramThe Geneva FoundationSan AntonioTX78234USA
| | | | - Beau Landis
- Bioengineering DivisionDraperCambridgeMA02139USA
| | | | - Joseph Urban
- Bioengineering DivisionDraperCambridgeMA02139USA
| | - Daniel Lang
- Bioengineering DivisionDraperCambridgeMA02139USA
| | - Bryan Teece
- Bioengineering DivisionDraperCambridgeMA02139USA
| | - WeiXuan Lai
- Bioengineering DivisionDraperCambridgeMA02139USA
| | - Rose Keating
- Bioengineering DivisionDraperCambridgeMA02139USA
| | - Diana Chiang
- Bioengineering DivisionDraperCambridgeMA02139USA
| | - Andriy I. Batchinsky
- Autonomous Reanimation and Evacuation (AREVA) Research ProgramThe Geneva FoundationSan AntonioTX78234USA
| | | |
Collapse
|
7
|
Bölükbas DA, Tas S. Current and Future Engineering Strategies for ECMO Therapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2023; 1413:313-326. [PMID: 37195538 DOI: 10.1007/978-3-031-26625-6_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
Extracorporeal membrane oxygenation (ECMO) is a last resort therapy for patients with respiratory failure where the gas exchange capacity of the lung is compromised. Venous blood is pumped through an oxygenation unit outside of the body where oxygen diffusion into the blood takes place in parallel to carbon dioxide removal. ECMO is an expensive therapy which requires special expertise to perform. Since its inception, ECMO technologies have been evolving to improve its success and minimize the complications associated with it. These approaches aim for a more compatible circuit design capable of maximum gas exchange with minimal need for anticoagulants. This chapter summarizes the basic principles of ECMO therapy with the latest advancements and experimental strategies aiming for more efficient future designs.
Collapse
Affiliation(s)
- Deniz A Bölükbas
- Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
- Lund Stem Cell Center, Lund University, Lund, Sweden
- Department of Clinical Sciences, Lund University, Lund, Sweden
- Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
| | - Sinem Tas
- Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
- Lund Stem Cell Center, Lund University, Lund, Sweden
- Department of Clinical Sciences, Lund University, Lund, Sweden
- Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
| |
Collapse
|